Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)

PHASE3TerminatedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 28, 2001

Study Completion Date

April 30, 2004

Conditions
Non-Small-Cell Lung CarcinomaLung CancerAnemia
Interventions
DRUG

Epoetin Alfa

Trial Locations (15)

T2N 4N2

Tom Baker Cancer Centre, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

R3E 0V9

Cancer Care Manitoba, Winnipeg

E2L 4L2

St. John Regional Hospital, Saint John

A1B 3V6

Newfoundland Cancer Treatment & Research Foundation, St. John's

B3H 1V7

Nova Scotia Cancer Centre, Halifax

P3E 5J1

Northeastern Ontario Regional Cancer Centre, Greater Sudbury

L8V 5C2

Hamilton Regional Cancer Centre (Juravinski), Hamilton

N6A 4L6

London Regional Cancer Centre, London

L2K 5K3

Hotel Dieu Hospital, Saint Catherines

M4C 3E7

Toronto East General Hospital, Toronto

M4N 3M5

Toronto Sunnybrook Regional Cancer Centre, Toronto

M5G 2M9

Princess Margaret Hospital, Toronto

N8W 2X3

Windsor Regional Cancer Centre, Windsor

H2W 1S6

McGill University Clinical Trials Operations, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ortho Biotech, Inc.

INDUSTRY

lead

Ontario Clinical Oncology Group (OCOG)

OTHER